Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07124949

Chinese Migrant Population Health Cohort

The Chinese Migrant Population Health Cohort is a prospective, multi-center study jointly initiated by Professor Yong Ji, President of Harbin Medical University, and Academician Guoqiang Chen, President of Hainan Medical University, in collaboration with regional partners. It targets older adults (≥60 years) who engage in seasonal migration between cold (Heilongjiang) and tropical (Hainan) regions. The primary objective is to investigate cardiovascular and metabolic disease risks, underlying biological and environmental mechanisms, and effective preventive strategies in this unique population.

Participants are recruited from both origin and destination sites and undergo standardized baseline assessments, including questionnaires, physical examinations, medical imaging, biospecimen collection (blood, stool, hair, nails), and environmental exposure monitoring. Longitudinal follow-up includes periodic reassessments, remote monitoring, and data linkage with hospital information systems to capture health outcomes.

The study aims to:

Define migration-related health risk profiles and disease phenotypes.

Elucidate biological and environmental mechanisms influencing disease onset and progression.

Develop AI-driven risk prediction models and evaluate targeted interventions through nested randomized controlled trials.

Translate findings into clinical guidelines and scalable cross-regional health management models.

This is the first cohort in China to systematically investigate the health impacts of seasonal migration in older adults. By integrating epidemiology, multi-omics, environmental data, and health policy translation, the study seeks to improve continuity of care, strengthen climate adaptation, and promote healthy ageing.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cardiovascular Diseases Ageing and Geriatric Health Climate Adaptation Metabolic Diseases Metabolic Disorders Nutritional and Metabolic Diseases

Age range

60 year–120 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Harbin Medical University

Harbin, Heilongjiang, 150086,, China

Location status: Recruiting

Location contact

Xizheng Wang, Doctor

CONTACT

[email protected]

+86 451 8660 5225

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Permanent residents of Harbin or Hainan who will continue to reside in Harbin or Hainan for the next 5 years.
  • Baseline age ≥60 years, with basic communication and comprehension abilities.
  • No confirmed diagnosis of end-stage major organic diseases (e.g., advanced heart failure, advanced liver failure, advanced kidney failure, malignant tumors).
  • Able to perform activities of daily living independently and capable of completing questionnaires and physical examinations.
  • Willing to participate in the study, provide written informed consent, accept long-term follow-up, and provide biological specimens.

Exclusion criteria

  • Occurrence of life-threatening acute events (e.g., myocardial infarction, acute heart failure, stroke) within the past 30 days.
  • Currently receiving chronic treatment with antiviral drugs (e.g., for HIV) or antipsychotic medications.
  • Presence of moderate to severe cognitive impairment preventing survey completion or follow-up cooperation.
  • Current acute infectious diseases such as influenza or fever.
  • Simultaneous participation in other interventional clinical studies.
  • Refusal to sign informed consent or unwillingness to provide biological specimens.
  • Any other condition deemed unsuitable for study participation by the investigators based on overall assessment.

Treatment and study plan

No intervention

Other

no intervention

Primary outcomes

  1. Number of Participants Experiencing First Major Cardiovascular Event

    Time frame: Up to 5 years from baseline

    First occurrence of myocardial infarction, stroke (ischemic or hemorrhagic), or cardiovascular death, confirmed through hospital records, death registries, and adjudication committee review.

Secondary outcomes

  1. Number of Participants with New-Onset Metabolic Disorders

    Time frame: Up to 5 years from baseline

    New-onset type 2 diabetes mellitus, dyslipidemia, or obesity as defined by standard clinical and laboratory criteria.

  2. Number of Deaths from Any Cause

    Time frame: Up to 5 years from baseline

    Death from any cause, verified through official death certificates and hospital records.

  3. Changes in Cardiometabolic Risk Factors

    Time frame: Baseline, 2 years, 4 years

    Longitudinal changes in blood pressure, fasting glucose, HbA1c, lipid profile, BMI, waist circumference, and body composition.

  4. Change in EQ-5D Quality of Life Score from Baseline

    Time frame: Baseline, 2 years, 4 years

    Changes in validated quality-of-life scales (e.g., EQ-5D).

  5. Change in Cognitive Function Score (MoCA) from Baseline

    Time frame: Baseline, 2 years, 4 years

    Mean change in Montreal Cognitive Assessment score.

Other outcomes

  1. Change in Carotid Intima-Media Thickness from Baseline

    Time frame: Baseline and follow-up imaging

    Mean change (mm) measured by carotid ultrasound.

  2. Change in Coronary Artery Calcium Score from Baseline

    Time frame: Baseline and follow-up imaging

    Mean change in Agatston score by CT angiography.

  3. Change in Plasma Metabolite Levels from Baseline

    Time frame: Baseline and follow-up biospecimen analyses

    Relative or absolute change in concentrations of targeted metabolites identified through mass spectrometry.

Study contacts

Contact information is provided by the study sponsor or research team.

Cheng Jin, Ph.D.

CONTACT

[email protected]

+86 153 13298872

Jinwei Tian, Ph.D.

CONTACT

[email protected]

+86 151 1451 8233

Sponsors and collaborators

Lead sponsor

Jinwei Tian

Other

Collaborators

  • Hainan Medical College

Registry information

Important dates

Study start
2025
Primary completion
2030
Study completion
2030
First posted
Aug 15, 2025
Registry last updated
Aug 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.